Gentronix
Private Company
Total funding raised: $500K
Overview
Gentronix is a specialized genotoxicity testing CRO with a strong scientific heritage, originating as a spin-out from the University of Manchester Institute of Science and Technology (UMIST). The company built its reputation on innovative predictive assays like GreenScreen HC and expanded into a full-service CRO offering GLP-compliant regulatory studies. In September 2024, Gentronix was acquired by the Scantox Group, integrating its expertise into a larger toxicology-focused CRO platform to offer broader service capabilities while continuing operations from its base at Alderley Park, Manchester.
Technology Platform
Proprietary GreenScreen HC and BlueScreen HC human cell-based reporter assays for predictive genotoxicity screening, complemented by a full suite of OECD/ICH-compliant in vitro and in vivo tests, including the TGRA Big Blue® transgenic rodent model.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Operates in a competitive CRO market with large, full-service players (e.g., Charles River, Labcorp) and other specialized toxicology providers. Differentiates through deep expertise as a pure-play genotoxicity specialist and its proprietary, widely recognized GreenScreen assay platform.